What's the difference between dexamethasone and hydroxycholoroquine/ivermectin/next-consipracy-theory?
It's been proven to work. There's no conspiracy, just pharmacology is hard, and people's random hunches typically don't work out.
Dexamethasone effectively treats the late, inflammatory stage of COVID19 where most virus is dead but still physically present.
The promise of other licensed medications is partially from their antiviral properties which means they're only expected to be effective as early stage medications.
So that's the difference. Different application. In the same way you wouldn't use Dexamethasone as an interchangeable treatment with monoclonal antibodies or remdesivir, which are also early stage treatments.
The point is that Ivermectin worked, Merck would be pushing it hard because it's a heck of a lot cheaper to make an existing drug you already make then get through R&D and clinical trials for a brand new drug which doesn't yet exist.
No, because it's out of patent. There's little profit to be made. Merck is instead pushing a new drug that they will have a monopoly on.
"Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19"
https://www.merck.com/news/merck-announces-supply-agreement-...
Big pharma 101.
As for Ivermectin effectiveness, it looks promising. There was an evidence based clinical review posted on Nature earlier this week:
"As per data available on 16 May 2021, 100% of 36 early treatment and prophylaxis studies report positive effects (96% of all 55 studies). Of these, 26 studies show statistically significant improvements in isolation. Random effects meta-analysis with pooled effects using the most serious outcome reported 79% and 85% improvement for early treatment and prophylaxis respectively (RR 0.21 [0.11–0.37] and 0.15 [0.09–0.25]). The results were similar after exclusion based sensitivity analysis: 81% and 87% (RR 0.19 [0.14–0.26] and 0.13 [0.07–0.25]), and after restriction to 29 peer-reviewed studies: 82% and 88% (RR 0.18 [0.11–0.31] and 0.12 [0.05–0.30]). Statistically significant improvements were seen for mortality, ventilation, hospitalization, cases, and viral clearance. 100% of the 17 Randomized Controlled Trials (RCTs) for early treatment and prophylaxis report positive effects, with an estimated improvement of 73% and 83% respectively (RR 0.27 [0.18–0.41] and 0.17 [0.05–0.61]), and 93% of all 28 RCTs."
https://www.nature.com/articles/s41429-021-00430-5